<DOC>
	<DOCNO>NCT00864253</DOCNO>
	<brief_summary>The main purpose research study compare safety , tolerability , anti tumor activity investigational drug , ABI-007 versus Dacarbazine patient metastatic melanoma previously receive chemotherapy . ABI-007 new preparation active drug paclitaxel . It contain medication prescription chemotherapy drug Abraxane® . Abraxane® approve FDA treatment metastatic breast cancer failure combination chemotherapy metastatic disease relapse within 6 month adjuvant chemotherapy . Dacarbazine approve FDA treatment melanoma . In study , ABI-007 Dacarbazine test therapy people yet cancer treatment diagnosis metastatic melanoma .</brief_summary>
	<brief_title>A Trial ABI-007 Versus Dacarbazine Previously Untreated Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically cytologically confirm cutaneous malignant melanoma evidence metastasis ( Stage IV ) . No prior cytotoxic chemotherapy metastatic malignant melanoma permit . Prior treatment kinase inhibitor cytokine permit . No prior adjuvant cytotoxic chemotherapy permit . Prior adjuvant therapy interferon , Granulocytemacrophage colonystimulating factor ( GMCSF ) and/or vaccine permit . Male nonpregnant nonlactating female , ≥ 18 year age . If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test Beta human chorionic gonadotropin ( ßhCG ) within 72 hour prior first study drug administration . If sexually active , patient must agree utilize contraception consider adequate appropriate investigator . No current active malignancy within past 3 year . Radiographicallydocumented measurable disease ( define presence least 1 radiographically document measurable lesion Patient follow blood count Baseline : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9 cells/L ; platelet ≥ 100 x 10^9 cells/L ; Hemoglobin ( Hgb ) ≥ 9 g/dL . Patient follow blood chemistry level Baseline : Aspartate aminotransferase ( AST ) glutamicoxaloacetic transaminase ( SGOT ) , alanine aminotransferase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5x upper limit normal range ( ULN ) ; ≤ 5.0 xULN hepatic metastasis present ; total bilirubin ≤ ULN ; creatinine ≤ 1.5 mg/dL . Lactate Dehydrogenase ( LDH ) ≤ 2.0 x ULNa Expected survival &gt; 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity . History current evidence brain metastasis , include leptomeningeal involvement . Patient preexist peripheral neuropathy National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Scale Grade ≥ 2 . Prior radiation target lesion permit clear progression lesion since radiation complete . Patient clinically significant concurrent illness . Patient , investigator 's opinion , unlikely able complete study End Study ( EOS ) visit . Patient currently enrol , enroll different clinical study investigational therapeutic procedure perform investigational therapy administer participate study . Marker study study evaluate biological correlate permit . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Malignant</keyword>
	<keyword>Abraxane</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Dtic-Dome</keyword>
</DOC>